Wednesday, February 10, 2010, 1:27PM AEST - The Australian Stockmarket closes in 2 hours and 38 minutes.
To create a watchlist or portfolio of shares, Register

Salix Pharmaceuticals Ltd. (SLXP)

 8:00AM AEST: 26.97 USD  Down 0.13 (0.48%)  
 MORE ON SLXP 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Salix Pharmaceuticals, Ltd. (NasdaqNM:SLXP) Delayed quote dataEdit
Last Trade:26.97 USD
Trade Time: 8:00AM AEST
Change:Down 0.13 (0.48%)
Prev Close:27.10
Open:27.41
Bid:26.37 x 100
Ask:28.01 x 100
1y Target Est:35.83
Day's Range:26.82 - 27.47
52wk Range:6.14 - 29.91
Volume:368,050
Avg Vol (3m):838,210
Market Cap:1.33B
P/E (ttm):N/A
EPS (ttm):-0.98
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add SLXP to Portfolio   Download Data

 HEADLINES 
•The Biggest Growth Stocks in Health Care
at Minyanville.com (Fri, Jan 29)
•Bulls On Board For A Big Run From Salix
at Forbes.com (Wed, Jan 27)
•Salix upgraded ahead of FDA's Xifaxan decision
AP (Wed, Jan 27)
•Salix Pharm upgraded by Oppenheimer
Briefing.com (Tue, Jan 26)
•Lightning Round: Boeing, Cadbury, Fifth Third Bancorp and More
at CNBC (Sat, Jan 9)
•Salix slapped with lawsuit over OsmoPrep
at bizjournals.com (Thu, Dec 24)
•Suits Commenced Against Maker of Prescription Cleansing Drug
PR Newswire (Thu, Dec 24)
•Salix to File for IBS Indication
Zacks.com (Thu, Dec 17)
•Salix, FDA discuss new drug application
at bizjournals.com (Sat, Dec 12)
•SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Fri, Dec 11)
•Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable Bowel Syndrome
Business Wire (Fri, Dec 11)
•SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Wed, Nov 25)
More Headlines for SLXP...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.89
EPS Est (in 2 years) (Dec-10) :0.22
Avg Rec (current)*:2.1
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing prescription drugs used in the treatment of gastrointestinal disorders in the United States.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices